Cargando…
Near-Infrared MAO A Inhibitor (NMI) Outperformed FDA-Approved Chemotherapeutic Agents in Brain and Other Cancers: A Bioinformatic Analysis of NCI60 Screening Data
Our previous work has shown that monoamine oxidase A (MAO A) is overexpressed in glioma and prostate cancer. Near-infrared dye conjugate MAO A Inhibitor (NMI) inhibited the growth of these cancers. This study investigated the effects of NMI on other cancers by NCI60 screening. Our results showed tha...
Autores principales: | Feng, Qianhua, Lian, Yuxuan, Qian, Yihan, Shih, Jean C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534240/ https://www.ncbi.nlm.nih.gov/pubmed/34679383 http://dx.doi.org/10.3390/brainsci11101318 |
Ejemplares similares
-
NMI and EMT
por: Samant, Rajeev S., et al.
Publicado: (2014) -
Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis
por: Li, Bin, et al.
Publicado: (2014) -
NMI: a potential biomarker for tumor prognosis and immunotherapy
por: He, Teng, et al.
Publicado: (2022) -
Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014) -
Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
por: Hariani, Gunjan D, et al.
Publicado: (2014)